A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
van den Bemt
B J F
BJ
Vos
K
K
den Broeder
A A
AA
Blom
M
M
Thurlings
R M
RM
Bartelds
G M
GM
Stapel
S O
SO
Barrera
P
P
Tak
P P
PP
Nurmohamed
M T
MT
Wolbink
G-J
GJ
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab; D000069285:Infliximab